Serum biomarkers in a mouse model of bacterial‐induced inflammatory bowel disease

Background: The diagnosis and classification of inflammatory bowel disease (IBD) require both clinical and histopathologic data. Serum biomarkers would be of considerable benefit to noninvasively monitor the progression of disease, assess effectiveness of therapies, and assist in understanding disease pathogenesis. Currently, there are limited noninvasive biomarkers for monitoring disease progression in animal IBD models, which are used extensively to develop new therapies and to understand IBD pathogenesis. Methods: Serum biomarkers of early and late IBD were identified using multianalyte profiling in mdr1a−/− mice with IBD triggered by infection with Helicobacter bilis. The correlation of changes in these biomarkers with histopathology scores and clinical signs in the presence and in the absence of antibiotic treatment was determined. Results: Serum levels of interleukin (IL)–11, IL‐17, 10‐kDa interferon‐&ggr;‐inducible protein (IP‐10), lymphotactin, monocyte chemoattractant protein (MCP)–1, and vascular cell adhesion molecule (VCAM)–1 were elevated early in IBD. In late, more severe IBD, serum levels of IL‐11, IP‐10, haptoglobin, matrix metalloproteinase–9, macrophage inflammatory protein (MIP)–1&ggr;, fibrinogen, immunoglobulin A, MIP‐3 beta (&bgr;), VCAM‐1, apolipoprotein (Apo) A1, and IL‐18 were elevated. All late serum biomarkers except Apo A1 correlated with histopathology scores. Antibiotic treatment improved clinical signs of IBD and decreased mean serum values of many of the biomarkers. For all biomarkers, the individual pathology scores correlated significantly with individual serum analyte levels after treatment. Conclusions: Serum analyte measurement is a useful, noninvasive method for monitoring disease in a mouse model of bacterial‐induced IBD.

[1]  P. Geurts,et al.  Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. , 2007, Biochemical pharmacology.

[2]  Mallika Singh,et al.  Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective , 2006, Clinical Cancer Research.

[3]  R. Gold,et al.  Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration , 2006, Clinical and experimental immunology.

[4]  E. Raines,et al.  Emerging roles for ectodomain shedding in the regulation of inflammatory responses , 2006, Journal of leukocyte biology.

[5]  J. Brain,et al.  Strain differences influence murine pulmonary responses to Stachybotrys chartarum. , 2006, American journal of respiratory cell and molecular biology.

[6]  B. Graham-Evans,et al.  Murine Embryonic Stem Cells Secrete Cytokines/Growth Modulators That Enhance Cell Survival/Anti‐Apoptosis and Stimulate Colony Formation of Murine Hematopoietic Progenitor Cells , 2006, Stem cells.

[7]  R. L. Grubbs,et al.  Effects of hyperglycemia and insulin therapy on outcome in a hyperglycemic septic model of critical illness. , 2006, The Journal of trauma.

[8]  X. Bossuyt.  Serologic markers in inflammatory bowel disease. , 2006, Clinical chemistry.

[9]  M. Sata,et al.  A form of circulating interleukin‐6 receptor component soluble gp130 as a potential interleukin‐6 inhibitor in inflammatory bowel disease , 2006, Clinical and experimental immunology.

[10]  L. Killar,et al.  Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. , 2005, Journal of autoimmunity.

[11]  J. Panés,et al.  Down‐Regulation of Endothelial Adhesion Molecules and Leukocyte Adhesion by Treatment with Superoxide Dismutase Is Beneficial in Chronic Immune Experimental Colitis , 2005, Inflammatory bowel diseases.

[12]  D. Cummins,et al.  Multiplex proteomic approaches to sepsis research: case studies employing new technologies , 2005, Expert review of proteomics.

[13]  Mark Tsang,et al.  Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia. , 2005, The American journal of pathology.

[14]  Agneta Karlsson,et al.  Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[15]  Y. Bouhnik.  [Diagnostic tools in inflammatory bowel diseases]. , 2005, La Revue du praticien.

[16]  F. Magro,et al.  Soluble Selectins, sICAM, sVCAM, and Angiogenic Proteins in Different Activity Groups of Patients with Inflammatory Bowel Disease , 2004, Digestive Diseases and Sciences.

[17]  C. McClain,et al.  Efficacy of a Transforming Growth Factor β2 Containing Nutritional Support Formula in a Murine Model of Inflammatory Bowel Disease , 2004, Journal of the American College of Nutrition.

[18]  C. Franklin,et al.  Analysis of Gene Expression in Ceca of Helicobacter hepaticus-Infected A/JCr Mice before and after Development of Typhlitis , 2003, Infection and Immunity.

[19]  D. Foell,et al.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease , 2003, Gut.

[20]  N. Tsuji,et al.  Serum Interleukin-18 Concentrations in Patients With Inflammatory Bowel Disease , 2002, Journal of immunotherapy.

[21]  Lillian Maggio-Price,et al.  Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. , 2002, The American journal of pathology.

[22]  R. Hershberg,et al.  Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[23]  M. Lukáš,et al.  [Initial experience with detection of Saccharomyces cerevisiae antibodies in patients with primary nonspecific inflammatory bowel disease]. , 2001, Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne.

[24]  N. Tsuji,et al.  Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. , 2001, Clinical chemistry.

[25]  M. Goggins,et al.  Soluble adhesion molecules in inflammatory bowel disease , 2001, Irish journal of medical science.

[26]  J. B. Seidelin,et al.  Clinical Reviews , 2000, American Journal of Gastroenterology.

[27]  J. C. Jones,et al.  References Subscriptions Permissions Email Alerts A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdr1a, Spontaneously Develop Colitis , 2013 .

[28]  S. Targan,et al.  Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. , 1998, Gastroenterology.

[29]  M. Manns,et al.  Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease , 1997, Journal of Gastroenterology.

[30]  M. Mohamadzadeh,et al.  Cytokine expression and antigen-presenting capacity of 4F7+ dendritic cells derived from dermis, spleen, and lymph nodes , 1997, Archives of Dermatological Research.

[31]  A. Bousvaros,et al.  Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. , 1996, Journal of pediatric gastroenterology and nutrition.

[32]  B. Beutler,et al.  Dendritic cells produce macrophage inflammatory protein-1 gamma, a new member of the CC chemokine family. , 1996, Journal of immunology.

[33]  N. Copeland,et al.  Molecular cloning and functional characterization of a novel member of the C-C chemokine family. , 1995, Journal of immunology.

[34]  F. D'armiento,et al.  Transglutaminases in Crohn's disease. , 1995, Gut.

[35]  O. Nielsen,et al.  Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease. , 1995, The American journal of gastroenterology.

[36]  O. Nielsen,et al.  Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease , 1994, Digestive Diseases and Sciences.

[37]  D. Taub,et al.  Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells , 1993, The Journal of experimental medicine.

[38]  A. Gearing,et al.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. , 1992, Biochemical and biophysical research communications.

[39]  C. Hawkey,et al.  Plasma and tissue interleukin‐2 receptor levels in inflammatory bowel disease , 1990, Clinical and experimental immunology.

[40]  G. Mazzacca,et al.  Serum transglutaminase in inflammatory bowel diseases. , 1990, Journal of clinical gastroenterology.

[41]  P. Munkholm,et al.  Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. , 2003, Scandinavian journal of gastroenterology.

[42]  M. Baggiolini,et al.  Short Communication Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis , 1999 .

[43]  B. Beutler,et al.  MIP-1γ : molecular cloning, expression, and biological activities of a novel CC chemokine that is constitutively secreted in vivo , 1995 .

[44]  F. Baldassarre,et al.  Serum and tissue transglutaminase correlates with the severity of inflammation in induced colitis in the rat. , 1992, Scandinavian journal of gastroenterology.